Latest News

Nvidia Analyst Raises Price Target By 78%: ‘Chipmaker Has Largest TAM Expansion Opportunity In All Of Tech’



Moderna: What You Need to Know Right Now

After a magnificent run, Moderna (MRNA) stock has recently lost some of its luster. Over the past month some notable of events have resulted in the shares shedding 30% of their value; weak earnings and outlook and Pfizer’s Covid pill have conspired to put the brakes on the extended rally. So, where do things stand right now for the vaccine giant? Oppenheimer’s Hartaj Singh recently met Moderna’s Investor Relations team to get the lowdown. First off, the team addressed the supply chain issues whi

The 4% rule is being debated — again — but here’s what you should do

Previous article

House Democrats Push Surprising Tax Break for the Rich

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News